Prestige Consumer Healthcare (PBH) to Release Quarterly Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is expected to announce its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.16 per share and revenue of $286.9320 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Parties can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The company had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The firm’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.09 earnings per share. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $64.38 on Wednesday. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55. The firm’s fifty day simple moving average is $62.79 and its 200 day simple moving average is $64.10. The stock has a market cap of $3.10 billion, a P/E ratio of 15.98, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43. Prestige Consumer Healthcare has a twelve month low of $57.25 and a twelve month high of $90.04.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the transaction, the vice president owned 42,329 shares in the company, valued at $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently bought and sold shares of PBH. Danske Bank A S bought a new stake in Prestige Consumer Healthcare during the 3rd quarter worth approximately $37,000. Brown Brothers Harriman & Co. purchased a new stake in shares of Prestige Consumer Healthcare in the third quarter worth $44,000. Geneos Wealth Management Inc. raised its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the period. CIBC Private Wealth Group LLC lifted its stake in shares of Prestige Consumer Healthcare by 142.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock valued at $69,000 after buying an additional 647 shares in the last quarter. Finally, State of Wyoming purchased a new position in shares of Prestige Consumer Healthcare during the 2nd quarter valued at $97,000. 99.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

PBH has been the topic of a number of research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Oppenheimer reduced their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, October 21st. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Jefferies Financial Group reduced their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $84.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).